{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:07:38Z","timestamp":1792375658899,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ucl.2025.01.009","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T22:59:46Z","timestamp":1741906786000},"page":"275-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Update on Adrenocortical Carcinoma"],"prefix":"10.1016","volume":"52","author":[{"given":"Zahra","family":"Sarrafan-Chaharsoughi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Yazdian Anari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan A.","family":"Malayeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Naraev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00001622-200401000-00004","article-title":"Adrenocortical cancer: recent clinical and molecular advances","volume":"16","author":"Sidhu","year":"2004","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2025.01.009_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1210\/clinem\/dgad199","article-title":"New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study","volume":"108","author":"Puglisi","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/biomedicines9020175","article-title":"Adrenocortical carcinoma: updates of clinical and pathological features after renewed world health organisation classification and pathology staging","volume":"9","author":"Lam","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ucl.2025.01.009_bib6","article-title":"Future directions in diagnosis, prognosis and disease monitoring of adrenocortical carcinoma: novel non-invasive biomarkers","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020174","article-title":"The role of biomarkers in adrenocortical carcinoma: a review of current evidence and future perspectives","volume":"9","author":"Mizdrak","year":"2021","journal-title":"Biomedicines"},{"issue":"18","key":"10.1016\/j.ucl.2025.01.009_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184671","article-title":"Identifying new potential biomarkers in adrenocortical tumors based on mRNA expression data using machine learning","volume":"13","author":"Marquardt","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib9","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-18-0608","article-title":"European society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020508","article-title":"Adjuvant therapy in adrenocortical carcinoma: reflections and future directions","volume":"12","author":"Bedrose","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.009_bib11","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in The Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ucl.2025.01.009_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2023.100759","article-title":"Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease","volume":"37","author":"Lib\u00e9","year":"2023","journal-title":"Cancer Treatment and Research Communications"},{"issue":"50","key":"10.1016\/j.ucl.2025.01.009_bib13","first-page":"885","article-title":"Deficits in the management of patients with adrenocortical carcinoma in Germany","volume":"107","author":"Johanssen","year":"2010","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101448","article-title":"Pediatric adrenocortical tumours","volume":"34","author":"Pinto","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib15","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.ucl.2025.01.009_bib16","doi-asserted-by":"crossref","unstructured":"Kerkhofs TMA. Adrenocortical carcinoma : a study on epidemiology diagnostics and treatment of a rare endocrine malignancy. [Doctoral Thesis, Maastricht University]. Maastricht University. 2015. Available at: https:\/\/doi.org\/10.26481\/dis.20151112tk.","DOI":"10.26481\/dis.20151112tk"},{"issue":"20","key":"10.1016\/j.ucl.2025.01.009_bib17","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","article-title":"Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors","volume":"31","author":"Cust\u00f3dio","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.009_bib18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jpedsurg.2013.02.017","article-title":"Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study","volume":"48","author":"McAteer","year":"2013","journal-title":"J\u00a0Pediatr Surg"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.20624","article-title":"Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil","volume":"47","author":"Pianovski","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12672-015-0244-z","article-title":"5th International ACC symposium: Hereditary predisposition to childhood ACC and the associated molecular phenotype: 5th International ACC Symposium Session: not just for kids","volume":"7","author":"Else","year":"2016","journal-title":"Horm Cancer"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.009_bib21","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/cancers11111804","article-title":"Penetrance of the TP53 R337H mutation and pediatric adrenocortical carcinoma incidence associated with environmental influences in a 12-year observational cohort in southern Brazil","volume":"11","author":"Costa","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ucl.2025.01.009_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.961650","article-title":"Pediatric adrenocortical carcinoma","volume":"13","author":"Ilanchezhian","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2006-923808","article-title":"Adrenocortical carcinoma -- improving patient care by establishing new structures","volume":"114","author":"Koschker","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mayocpiqo.2017.11.002","article-title":"Clinical, biochemical, and radiological characteristics of a single-center retrospective cohort of 705 large adrenal tumors","volume":"2","author":"I\u00f1iguez-Ariza","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.ucl.2025.01.009_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fendo.2016.00099","article-title":"Prognostic factors for adrenocortical carcinoma outcomes","volume":"7","author":"Scollo","year":"2016","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.009_bib26","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1530\/EJE-18-0027","article-title":"Management of endocrine disease: adrenocortical carcinoma: differentiating the good from the poor prognosis tumors","volume":"178","author":"Jouinot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib27","article-title":"Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker","volume":"3","author":"Kovach","year":"2015","journal-title":"Discoveries"},{"key":"10.1016\/j.ucl.2025.01.009_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1100207","article-title":"Nonfunctional ectopic adrenocortical carcinoma in the lung: a case report and literature review","volume":"13","author":"Nie","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib29","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1530\/EJE-16-0461","article-title":"Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis","volume":"175","author":"Dinnes","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.009_bib30","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2214\/AJR.16.17758","article-title":"Update on CT and MRI of adrenal nodules","volume":"208","author":"Schieda","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/jc.2005-1540","article-title":"Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography","volume":"91","author":"Leboulleux","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.009_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/RLU.0000000000004593","article-title":"Positive correlation between 18 F-FDG uptake and tumor-proliferating antigen ki-67 expression in adrenocortical carcinomas","volume":"48","author":"Lib\u00e9","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.009_bib33","first-page":"728","article-title":"Role of (18)F-fluorodeoxyglucose positron-emission tomography\/computed tomography in restaging of adrenocortical carcinoma","volume":"28","author":"Ozturk","year":"2023","journal-title":"Rep Practical Oncol Radiother"},{"issue":"8","key":"10.1016\/j.ucl.2025.01.009_bib34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/PAS.0b013e31825a6308","article-title":"Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE","volume":"36","author":"Tissier","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.ucl.2025.01.009_bib35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/00000478-200212000-00009","article-title":"Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors","volume":"26","author":"Aubert","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043585","article-title":"Steroidogenic factor 1, a goldilocks transcription factor from adrenocortical organogenesis to malignancy","volume":"24","author":"Relav","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0090-4295(00)00852-9","article-title":"Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors","volume":"57","author":"Terzolo","year":"2001","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after Complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s12020-020-02583-z","article-title":"Insulin-like growth factor 2 (IGF2) expression in adrenocortical disease due to PRKAR1A mutations compared to other benign adrenal tumors","volume":"72","author":"Nadella","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12020-019-02033-5","article-title":"IGF2 role in adrenocortical carcinoma biology","volume":"66","author":"Pereira","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.ucl.2025.01.009_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1261860","article-title":"Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review","volume":"14","author":"Buczy\u0144ska","year":"2023","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12672-020-00385-3","article-title":"Advanced adrenocortical carcinoma (ACC): a review with focus on second-line therapies","volume":"11","author":"Ardolino","year":"2020","journal-title":"Hormones and Cancer"},{"key":"10.1016\/j.ucl.2025.01.009_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humpath.2016.08.006","article-title":"Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis","volume":"58","author":"Papathomas","year":"2016","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.surg.2020.05.039","article-title":"Molecular genomic profiling of adrenocortical cancers in clinical practice","volume":"169","author":"Darabi","year":"2021","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.009_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111501","article-title":"The diagnostic, prognostic and therapeutic role of miRNAs in adrenocortical carcinoma: a systematic review","volume":"9","author":"Mytareli","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ucl.2025.01.009_bib47","first-page":"195","article-title":"microRNAs as potential biomarkers in adrenocortical cancer: progress and challenges","volume":"6","author":"Cherradi","year":"2015","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.ucl.2025.01.009_bib48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/oncolo\/oyae029","article-title":"Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches","volume":"29","author":"Chukkalore","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib49","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026187","article-title":"Inherited TP53 mutations and the Li-fraumeni syndrome","volume":"7","author":"Guha","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib50","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib51","first-page":"49","article-title":"Birt-Hogg-Dub\u00e9 Syndrome and coexistence with adrenocortical carcinoma","volume":"25","author":"Kalloniati","year":"2021","journal-title":"Hippokratia"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12022-023-09748-2","article-title":"FLCN-driven functional adrenal cortical carcinoma with high mitotic tumor grade: extending the endocrine manifestations of Birt-Hogg-Dub\u00e9 Syndrome","volume":"34","author":"Hofstedter","year":"2023","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2011.12.008","article-title":"Association of adrenocortical carcinoma with familial cancer susceptibility syndromes","volume":"351","author":"Else","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2011-2244","article-title":"A\u00a0large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer","volume":"97","author":"Anselmo","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.009_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8060054","article-title":"Control of Wnt receptor turnover by R-spondin-ZNRF3\/RNF43 signaling module and its dysregulation in cancer","volume":"8","author":"Hao","year":"2016","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib56","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harbor Perspect Biol"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1078-0432.CCR-06-2085","article-title":"Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity","volume":"13","author":"Lib\u00e8","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib58","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.3390\/ijms24043585","article-title":"Steroidogenic Factor 1, a goldilocks transcription factor from adrenocortical organogenesis to malignancy","volume":"24","author":"Relav","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.009_bib59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/oncolo\/oyac061","article-title":"Blood-based next-generation sequencing in adrenocortical carcinoma","volume":"27","author":"Nazha","year":"2022","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.ucl.2025.01.009_bib60","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.ucl.2025.01.009_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16234061","article-title":"A\u00a0review on mitotane: a target therapy in adrenocortical carcinoma","volume":"16","author":"Flauto","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030304","article-title":"Immunotherapy in adrenocortical carcinoma: predictors of response, efficacy, safety, and mechanisms of resistance","volume":"9","author":"Araujo-Castro","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ucl.2025.01.009_bib64","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/clinem\/dgae109","article-title":"Expression and prognostic relevance of PD-1, PD-L1, and CTLA-4 immune checkpoints in adrenocortical carcinoma","volume":"109","author":"Landwehr","year":"2024","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2025.01.009_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2015.11.020","article-title":"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy","volume":"55","author":"Tokito","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.009_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040541","article-title":"Low CD8\u207a T cell infiltration and high PD-L1 expression are associated with level of CD44\u207a\/CD133\u207a cancer stem cells and predict an unfavorable prognosis in pancreatic cancer","volume":"11","author":"Hou","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib67","article-title":"Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options","volume":"2","author":"Al-Ward","year":"2022","journal-title":"Endocr Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.009_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101408","article-title":"Surgery for adrenocortical carcinoma: when and how?","volume":"34","author":"Sinclair","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.009_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40463-018-0273-z","article-title":"Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma","volume":"47","author":"Xu","year":"2018","journal-title":"J\u00a0Otolaryngol-Head & Neck Surg"},{"key":"10.1016\/j.ucl.2025.01.009_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211033103","article-title":"Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment","volume":"12","author":"Shariq","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.009_bib71","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American Association of Clinical Endocrinology Disease State clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ucl.2025.01.009_bib73","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.009_bib74","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.009_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO open"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T18:34:18Z","timestamp":1750185258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0094014325000096"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.01.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Adrenocortical Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}